ArticleOncogene2025
KPNA2 silencing sensitizes triple-negative breast cancer to chemotherapy by promoting multipolar division and suppressing DNA damage repair.
Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most common malignancies among women. Triple-negative breast cancer (TNBC) is a distinct subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Consequently, patients with TNBC do not benefit from endocrine therapy or HER2-targeted therapy, leaving conventional chemotherapy as the primary treatment option. Unfortunately, less than 30% of patients with TNBC achieve a complete response to chemotherapy, and many develop resistance, highlighting the urgent need to identify novel therapeutic targets to overcome chemoresistance. In this study, we analyzed breast cancer data from The Cancer Genome Atlas (TCGA) and discovered that KPNA2 was significantly overexpressed in the basal subtype of the PAM50 classification. Furthermore, KPNA2 expression is strongly associated with the prognosis of TNBC patients undergoing chemotherapy. Through in vitro and in vivo experiments, we demonstrated that silencing of KPNA2 enhances TNBC sensitivity to chemotherapy by promoting multipolar division and suppressing homologous recombination repair (HR), a critical DNA damage repair mechanism. Mechanistically, immunoprecipitation mass spectrometry (IP-MS) identified KIFC1 as a downstream effector of KPNA2. KPNA2 not only binds to the nuclear localization signal (NLS) of KIFC1 to regulate its nuclear translocation but also influences the ubiquitination levels of the KIFC1 protein. Additionally, RNA-seq analysis revealed that KPNA2 and KIFC1 are involved in the NF-κB signaling pathway. The KPNA2/KIFC1/NF-κB pathway/HR-related genes axis provides a comprehensive explanation of how KPNA2 influences DNA damage repair. Overall, our findings shed light on the molecular mechanisms underlying chemoresistance in TNBC. This study provides compelling evidence supporting KPNA2 as a promising therapeutic target for overcoming chemoresistance in TNBC.
Indexed as
Identifiers
40968253What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.